{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:12:10Z","timestamp":1789193530774,"version":"build-2803163510"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T00:00:00Z","timestamp":1626134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T00:00:00Z","timestamp":1626134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100018712","name":"Universitatea de Medicin\u0103 \u015fi Farmacie Iuliu Ha\u0163ieganu Cluj-Napoca","doi-asserted-by":"publisher","award":["PCD 1529\/32\/18.01.19"],"award-info":[{"award-number":["PCD 1529\/32\/18.01.19"]}],"id":[{"id":"10.13039\/501100018712","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Recent drug safety concerns described fluoroquinolone (FQ)-induced serious musculoskeletal reactions. The objective of this study was to characterize reports with FQ-associated disabling musculoskeletal disorders, from VigiBase. The analysis included all FQ-induced musculoskeletal and connective tissue disorders adverse drug reaction (ADR) reports (up to July-2019), (disabling\/incapacitating, or recovered\/resolved with sequelae or fatal). We described aspects like reporter, suspected FQs, ADRs, associated corticosteroid therapy. We also looked into the disproportionality data in terms of proportional reporting ratio (PRR) and information component (IC) values. A total of 5355 reports with 13,563 ADRs and 5558 FQs were reported. The majority of reports were for patients aged 18\u201364 (62.67%), and the female gender prevailed (61.76%). Consumers reported almost half (45.99%), with a peak in reporting rates in 2017. Top reported ADRs were arthralgia (16.34%), tendonitis (11.04%), pain in extremity (9.98%), tendon pain (7.63%), and myalgia (7.17%). Top suspected FQs were levofloxacin (50.04%), ciprofloxacin (38.41%), moxifloxacin (5.16%), ofloxacin (3.17%) and norfloxacin (1.01%). For these, FQs-ADR association was supported by the disproportionality analysis. Corticosteroids were associated with about 7% of tendon related reports. The results augment the existing data on FQs safety concerns, specifically their potential effect on the musculoskeletal system.<\/jats:p>","DOI":"10.1038\/s41598-021-93763-y","type":"journal-article","created":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T10:24:02Z","timestamp":1626171842000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["A VigiBase descriptive study of fluoroquinolone induced disabling and potentially permanent musculoskeletal and connective tissue disorders"],"prefix":"10.1038","volume":"11","author":[{"given":"Madalina","family":"Huruba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2109-8409","authenticated-orcid":false,"given":"Andreea","family":"Farcas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Corneliu","family":"Leucuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camelia","family":"Bucsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Sipos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Mogosan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,13]]},"reference":[{"issue":"1","key":"93763_CR1","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2174\/157488607779315516","volume":"2","author":"A Conforti","year":"2008","unstructured":"Conforti, A. et al. Musculoskeletal adverse drug reactions: A review of literature and data from adr spontaneous reporting databases. Curr. Drug Saf. 2(1), 47\u201363 (2008).","journal-title":"Curr. Drug Saf."},{"issue":"6","key":"93763_CR2","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","volume":"72","author":"JL Montastruc","year":"2011","unstructured":"Montastruc, J. L., Sommet, A., Bagheri, H. & Lapeyre-Mestre, M. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br. J. Clin. Pharmacol. 72(6), 905\u2013908 (2011).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"93763_CR3","unstructured":"European Medicines Agency: EMA\/818158\/2018. Pharmacovigilance Risk Assessment Committee (PRAC), 16 October 2018. Assessment Report. Referral Under Article 31 of Directive 2001\/83\/EC Resulting from Pharmacovigilance Data. https:\/\/www.ema.europa.eu\/en\/documents\/referral\/quinolone-fluoroquinolone-article-31-referral-assessment-report_en.pdf (2018)."},{"issue":"3","key":"93763_CR4","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.ijantimicag.2008.08.004","volume":"33","author":"J Sendzik","year":"2009","unstructured":"Sendzik, J., Lode, H. & Stahlmann, R. Quinolone-induced arthropathy: An update focusing on new mechanistic and clinical data. Int. J. Antimicrob. Agents. 33(3), 194\u2013200 (2009).","journal-title":"Int. J. Antimicrob. Agents."},{"issue":"6A","key":"93763_CR5","doi-asserted-by":"publisher","first-page":"35S","DOI":"10.1016\/0002-9343(91)90308-K","volume":"91","author":"DR Patterson","year":"1991","unstructured":"Patterson, D. R. Quinolone toxicity: Methods of assessment. Am. J. Med. 91(6A), 35S-37S (1991).","journal-title":"Am. J. Med."},{"issue":"2","key":"93763_CR6","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1177\/0009922815599959","volume":"55","author":"J Binz","year":"2016","unstructured":"Binz, J., Adler, C. K. & So, T. Y. The risk of musculoskeletal adverse events with fluoroquinolones in children: What is the verdict now?. Clin. Pediatr. (Phila). 55(2), 107\u2013110 (2016).","journal-title":"Clin. Pediatr. (Phila)."},{"issue":"1","key":"93763_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40545-019-0168-z","volume":"12","author":"AS Almulhim","year":"2019","unstructured":"Almulhim, A. S., Aldayyen, A., Yenina, K., Chiappini, A. & Khan, T. M. Optimization of antibiotic selection in the emergency department for urine culture follow ups, a retrospective pre-post intervention study: Clinical pharmacist efforts. J. Pharm. Policy Pract. 12(1), 1\u20137 (2019).","journal-title":"J. Pharm. Policy Pract."},{"issue":"1","key":"93763_CR8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2165\/00003495-200262010-00002","volume":"62","author":"GG Zhanel","year":"2002","unstructured":"Zhanel, G. G. et al. A critical review of the fluoroquinolones: Focus on respiratory infections. Drugs 62(1), 13\u201359 (2002).","journal-title":"Drugs"},{"issue":"9","key":"93763_CR9","doi-asserted-by":"publisher","first-page":"789","DOI":"10.2165\/11536810-000000000-00000","volume":"33","author":"F Lapi","year":"2010","unstructured":"Lapi, F. et al. Safety profile of the fluoroquinolones. Drug Saf. 33(9), 789\u2013799 (2010).","journal-title":"Drug Saf."},{"issue":"7","key":"93763_CR10","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.bjps.2006.08.005","volume":"61","author":"AU Akali","year":"2008","unstructured":"Akali, A. U. & Niranjan, N. S. Management of bilateral Achilles tendon rupture associated with ciprofloxacin: A review and case presentation. J. Plast. Reconstr. Aesthetic Surg. 61(7), 830\u2013834 (2008).","journal-title":"J. Plast. Reconstr. Aesthetic Surg."},{"issue":"2","key":"93763_CR11","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1177\/039463201102400227","volume":"24","author":"A Pantalone","year":"2011","unstructured":"Pantalone, A., Abate, M., D\u2019ovido, C., Carnevale, A. & Salini, V. Diagnostic failure of ciprofloxacin-induced spontaneous bilateral Achilles tendon rupture: Case-report and medical-legal considerations. Int. J. Immunopathol. Pharmacol. 24(2), 519\u2013522 (2011).","journal-title":"Int. J. Immunopathol. Pharmacol."},{"issue":"3","key":"93763_CR12","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1046\/j.1365-2125.1999.00016.x","volume":"48","author":"PD Van der Linden","year":"1999","unstructured":"Van der Linden, P. D., Van de Lei, J., Nab, H. W., Knol, A. & Stricker, B. H. C. Achilles tendinitis associated with fluoroquinolones. Br. J. Clin. Pharmacol. 48(3), 433\u2013437 (1999).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"93763_CR13","unstructured":"FDA (US Food and Drug Administration). FDA Drug Safety Communication: FDA Updates Warnings for Oral and Injectable Fluoroquinolone Antibiotics Due to Disabling Side Effects. Safety Announcement. https:\/\/www.fda.gov\/media\/99425\/download (2016)"},{"issue":"5","key":"93763_CR14","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1177\/009286150804200501","volume":"42","author":"M Lindquist","year":"2008","unstructured":"Lindquist, M. VigiBase, the WHO Global ICSR Database System: Basic facts. Drug Inf. J. 42(5), 409\u2013419 (2008).","journal-title":"Drug Inf. J."},{"key":"93763_CR15","unstructured":"European Medicines Agency: CPMP\/ICH\/377\/95. ICH Topic E 2 A Clinical Safety Data Management: Definitions and Standards for Expedited Reporting. June 1995. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use_en-15.pdf."},{"key":"93763_CR16","unstructured":"WHO. Collaborating Centre for Drug Statistics Methodology. ATC\/DDD Index 2020. https:\/\/www.whocc.no\/atc_ddd_index\/ (2020)."},{"issue":"1","key":"93763_CR17","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s40264-019-00870-x","volume":"43","author":"EJ Baan","year":"2020","unstructured":"Baan, E. J. et al. Exploratory study of signals for asthma drugs in children, using the eudravigilance database of spontaneous reports. Drug Saf. 43(1), 7\u201316 (2020).","journal-title":"Drug Saf."},{"issue":"5","key":"93763_CR18","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s00228-014-1658-1","volume":"70","author":"B Grundmark","year":"2014","unstructured":"Grundmark, B., Holmberg, L., Garmo, H. & Zethelius, B. Reducing the noise in signal detection of adverse drug reactions by standardizing the background: A pilot study on analyses of proportional reporting ratios-by-therapeutic area. Eur. J. Clin. Pharmacol. 70(5), 627\u2013635 (2014).","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"18","key":"93763_CR19","first-page":"1","volume":"2045","author":"J Salem","year":"2018","unstructured":"Salem, J. et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: An observational, retrospective, pharmacovigilance study. Lancet Oncol. 2045(18), 1\u201311 (2018).","journal-title":"Lancet Oncol."},{"key":"93763_CR20","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.2147\/TCRM.S137144","volume":"13","author":"A Arora","year":"2017","unstructured":"Arora, A., Jalali, R. K. & Vohora, D. Relevance of the Weber effect in contemporary pharmacovigilance of oncology drugs. Ther. Clin. Risk Manag. 13, 1195\u20131203 (2017).","journal-title":"Ther. Clin. Risk Manag."},{"issue":"11","key":"93763_CR21","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1517\/14740338.2015.1085968","volume":"14","author":"RM Arabyat","year":"2015","unstructured":"Arabyat, R. M., Raisch, D. W., McKoy, J. M. & Bennett, C. L. Fluoroquinolone-associated tendon-rupture: A summary of reports in the Food and Drug Administration\u2019s adverse event reporting system. Expert Opin. Drug Saf. 14(11), 1653\u20131660 (2015).","journal-title":"Expert Opin. Drug Saf."},{"issue":"2","key":"93763_CR22","first-page":"117","volume":"5","author":"T Toki","year":"2018","unstructured":"Toki, T. & Ono, S. Spontaneous reporting on adverse events by consumers in the United States: An analysis of the food and drug administration adverse event reporting system database. Drugs 5(2), 117\u2013128 (2018).","journal-title":"Drugs"},{"issue":"6","key":"93763_CR23","doi-asserted-by":"publisher","first-page":"515","DOI":"10.2165\/00002018-200831060-00006","volume":"31","author":"J De Langen","year":"2008","unstructured":"De Langen, J., van Hunsel, F., Passier, A., de Jong-van den Berg, L. & van Grootheest, K. Adverse drug reaction reporting by patients in the Netherlands. Drug Saf. 31(6), 515\u2013524 (2008).","journal-title":"Drug Saf."},{"key":"93763_CR24","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s40264-017-0594-2","volume":"41","author":"S Watson","year":"2018","unstructured":"Watson, S. et al. Safety concerns reported by patients identified in a collaborative signal detection workshop using VigiBase: Results and reflections from Lareb and Uppsala Monitoring Centre. Drug Saf. 41, 203\u2013212 (2018).","journal-title":"Drug Saf."},{"issue":"9","key":"93763_CR25","doi-asserted-by":"publisher","first-page":"e73166","DOI":"10.1371\/journal.pone.0073166","volume":"8","author":"KM Hakkarainen","year":"2013","unstructured":"Hakkarainen, K. M., Sundell, K. A., Petzold, M. & Ha, S. Prevalence and perceived preventability of self- reported adverse drug events: A population-based survey of 7099 adults. PLoS ONE 8(9), e73166 (2013).","journal-title":"PLoS ONE"},{"issue":"10","key":"93763_CR26","doi-asserted-by":"publisher","first-page":"889","DOI":"10.2165\/00002018-200629100-00006","volume":"29","author":"G Corrao","year":"2006","unstructured":"Corrao, G. et al. Evidence of tendinitis provoked by fluoroquinolone treatment a case-control study. Drug Saf. 29(10), 889\u2013896 (2006).","journal-title":"Drug Saf."},{"key":"93763_CR27","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1056\/NEJM199409153311116","volume":"331","author":"K Huston","year":"1994","unstructured":"Huston, K. Achilles tendinitis and tendon rupture due to fluoroquinolone antibiotics. N. Engl. J. Med. 331, 748 (1994).","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"93763_CR28","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1136\/emermed-2016-205965.2","volume":"33","author":"JP Baombe","year":"2009","unstructured":"Baombe, J. P. & Ford, R. Do fluoroquinolones increase the incidence of tendinopathy?. Emerg. Med. J. 33(7), 519\u2013522 (2009).","journal-title":"Emerg. Med. J."},{"issue":"8","key":"93763_CR29","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/pds.3285","volume":"21","author":"K Hori","year":"2012","unstructured":"Hori, K., Yamakawa, K., Yoshida, N., Ohnishi, K. & Kawakami, J. Detection of fluoroquinolone-induced tendon disorders using a hospital database in Japan. Pharmacoepidemiol. Drug Saf. 21(8), 886\u2013889 (2012).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"5","key":"93763_CR30","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s00228-007-0265-9","volume":"63","author":"J Sode","year":"2007","unstructured":"Sode, J., Obel, N., Hallas, J. & Lassen, A. Use of fluroquinolone and risk of Achilles tendon rupture: A population-based cohort study. Eur. J. Clin. Pharmacol. 63(5), 499\u2013503 (2007).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"93763_CR31","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.urology.2017.10.017","volume":"113","author":"AL Godoy-Santos","year":"2018","unstructured":"Godoy-Santos, A. L. et al. Fluoroquinolones and the risk of achilles tendon disorders: Update on a neglected complication. Urology 113, 20\u201325 (2018).","journal-title":"Urology"},{"issue":"9","key":"93763_CR32","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s40264-013-0089-8","volume":"36","author":"AL Stephenson","year":"2013","unstructured":"Stephenson, A. L., Wu, W., Cortes, D. & Rochon, P. A. Tendon injury and fluoroquinolone use: A systematic review. Drug Saf. 36(9), 709\u2013721 (2013).","journal-title":"Drug Saf."},{"issue":"2","key":"93763_CR33","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s41669-016-0007-y","volume":"1","author":"ZS Almalki","year":"2017","unstructured":"Almalki, Z. S., Yue, X., Xia, Y., Wigle, P. R. & Guo, J. J. Utilization, spending, and price trends for quinolones in the us medicaid programs: 25 years\u2019 experience 1991\u20132015. PharmacoEconomics Open 1(2), 123\u2013131 (2017).","journal-title":"PharmacoEconomics Open"},{"key":"93763_CR34","unstructured":"NHS. North Central London Joint Formulary Committee. Safe prescribing of fluoroquinolones Position Statement. https:\/\/www.ncl-mon.nhs.uk\/wp-content\/uploads\/Guidelines\/5_Fluoroquinolones_Safe_Prescribing_P (2019)."},{"issue":"5","key":"93763_CR35","doi-asserted-by":"publisher","first-page":"e1034","DOI":"10.1542\/peds.2016-2706","volume":"138","author":"MA Jackson","year":"2016","unstructured":"Jackson, M. A. et al. The use of systemic and topical fluoroquinolones. Pediatrics 138(5), e1034 (2016).","journal-title":"Pediatrics"},{"issue":"11","key":"93763_CR36","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1002\/pds.1214","volume":"15","author":"JD Seeger","year":"2006","unstructured":"Seeger, J. D. et al. Achilles tendon rupture and its association with fluoroquinolone antibiotics and other potential risk factors in a managed care population. Pharmacoepidemiol. Drug Saf. 15(11), 784\u2013792 (2006).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"4","key":"93763_CR37","doi-asserted-by":"publisher","first-page":"203","DOI":"10.4103\/0970-258X.218673","volume":"30","author":"YS Kim","year":"2017","unstructured":"Kim, Y. S., Park, J. M., Moon, Y. S. & Han, S. H. Assessment of pain in the elderly: A literature review. Natl. Med. J. India 30(4), 203\u2013207 (2017).","journal-title":"Natl. Med. J. India"},{"issue":"7","key":"93763_CR38","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.nmd.2010.05.003","volume":"20","author":"A Echaniz-Laguna","year":"2010","unstructured":"Echaniz-Laguna, A., Mohr, M., Lannes, B. & Tranchant, C. Myopathies in the elderly: A hospital-based study. Neuromuscul. Disord. 20(7), 443\u2013447 (2010).","journal-title":"Neuromuscul. Disord."},{"issue":"3","key":"93763_CR39","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2165\/11531490-000000000-00000","volume":"27","author":"R Stahlmann","year":"2010","unstructured":"Stahlmann, R. & Lode, H. Safety considerations of fluoroquinolones in the elderly: An update. Drugs Aging 27(3), 193\u2013209 (2010).","journal-title":"Drugs Aging"},{"key":"93763_CR40","unstructured":"Horn, J. R. & Hansten, P. D. Fluoroquinolones and steroids: An achilles heel interaction. Pharm. Times. 82(4), (2016)."},{"issue":"12","key":"93763_CR41","doi-asserted-by":"publisher","first-page":"1228.e23","DOI":"10.1016\/j.amjmed.2012.05.027","volume":"125","author":"BL Wise","year":"2012","unstructured":"Wise, B. L., Peloquin, C., Choi, H., Lane, N. E. & Zhang, Y. Impact of age, sex, obesity, and steroid use on quinolone-associated tendon disorders. Am. J. Med. 125(12), 1228.e23-1228.e28 (2012).","journal-title":"Am. J. Med."},{"issue":"90","key":"93763_CR42","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1086\/375078","volume":"36","author":"Y Khaliq","year":"2003","unstructured":"Khaliq, Y. & Zhanel, G. Fluoroquinolone-associated tendinopathy: A critical review of the literature. Clin. Infect. Dis. 36(90), 1404\u20131410 (2003).","journal-title":"Clin. Infect. Dis."},{"issue":"SUPPL1","key":"93763_CR43","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.4103\/0976-500X.120955","volume":"4","author":"C Palleria","year":"2013","unstructured":"Palleria, C. et al. Limitations and obstacles of the spontaneous adverse drugs reactions reporting: Two \u201cchallenging\u201d case reports. J. Pharmacol. Pharmacother. 4(SUPPL1), S66-72 (2013).","journal-title":"J. Pharmacol. Pharmacother."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-93763-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-93763-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-93763-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T11:10:47Z","timestamp":1670065847000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-93763-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,13]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["93763"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-93763-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,13]]},"assertion":[{"value":"22 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14375"}}